Researchers have discovered that the antidepressant vortioxetine effectively combats glioblastoma, a deadly brain tumor, in ...

This medication is used to treat depression. Other drugs that can cause bleeding/bruising (including antiplatelet drugs such as clopidogrel, NSAIDs such as ibuprofen, blood thinners such as ...

Lundbeck with its depression drug Trintellix/Brintellix and its Rexulti schizophrenia drug, which is marketed in partnership with Otsuka, could see sales increase in a post-COVID world.

Glioblastoma is a particularly aggressive brain tumor that at present is incurable. Cancer doctors can extend patients' life expectancy through operations, radiation, chemotherapy or surgical ...

Vortioxetine hydrobromide is under clinical development by H. Lundbeck and currently in Phase II for Bipolar Disorder (Manic Depression).

At some point in our lives, most of us will need to take medication, either briefly or long term. Research shows ...

The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for ...

The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The firm also points to the importance of Lundbeck's patent portfolio, particularly noting the patent expirations for Rexulti in 2029 and for Trintellix outside the United States beginning in 2028.